ALXN Financial Facts
Operating income: 194.71MIncome tax provision: 55.02M
See Full Income Statement
Treasury stock, at cost: -1.04B
Trade accounts receivable, net: 609.3M
See Full Balance Sheet
Alexion Pharmaceuticals, Inc. (ALXN) Earnings
|
Expand Research on ALXN
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +18.2% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +1.3% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4/30/21 |  |
Q121 | $3.52 | $3.16 | +$0.36 | $1.64B | $1.58B | N/A |  | | Details |
| 2/4/21 | |
Q420 | $2.96 | $2.56 | +$0.40 | $1.59B | $1.52B | N/A | | | Details |
| 10/29/20 | |
Q320 | $3.24 | $2.58 | +$0.66 | $1.59B | $1.42B | = | | | Details |
| 7/30/20 | |
Q220 | $3.11 | $2.59 | +$0.52 | $1.44B | $1.28B | = | | | Details |
| 5/6/20 | |
Q120 | $3.22 | $2.71 | +$0.51 | $1.44B | $1.36B | = | | | Details |
| 1/30/20 | |
Q419 | $2.71 | $2.60 | +$0.11 | $1.38B | $1.31B | = | | | Details |
| 10/23/19 | |
Q319 | $2.79 | $2.47 | +$0.32 | $1.26B | $1.24B |  |
| | Details |
| 7/24/19 | |
Q219 | $2.64 | $2.34 | +$0.30 | $1.2B | $1.17B | |
| | Details |
